OXB’s Surging US Growth With New North Carolina Facility
OXB has acquired an FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina, from a subsidiary of National...
Jon Napitupulu
Lexeo Announces Positive LX2006 Data for FA Cardiomyopathy
Lexeo Therapeutics reported that the FDA is open to a pooled-data strategy supporting an accelerated approval filing for LX2006,...
New Leqembi Subcutaneous Injection for Alzheimer’s Now in US
Eisai and Biogen have made Leqembi iqlik, a weekly 360 mg subcutaneous autoinjector, available in the U.S. as a...
High Court Approves MSD’s Successful Acquisition of Verona
MSD, the tradename of Merck & Co., will acquire Verona Pharma for $107 per American Depositary Share in a...
Equillium Announces Important Leadership, Corporate Updates
Equillium has restructured its leadership and governance while exiting a legacy collaboration to concentrate resources on a single internal...
Profusa Adds Leading French CLI Surgeon to Customer Base
Profusa has expanded its European footprint through a collaboration with Yann Gouëffic, professor of vascular surgery at Groupe Hospitalier...
Kraig Labs’ Breakthrough Unlocks Powerful Spider Silk Tech
Kraig Biocraft Laboratories has announced commercial-scale production of spider silk using genetically engineered silkworms, converting a long-celebrated biomaterial into...
Hutchmed Spotlights New Clinical Data for ESMO Congress 2025
HUTCHMED will take a broad slate of oncology data to ESMO 2025, headlined by the FRUSICA-2 registration study of...
Xilio to Present New Immunotherapy Data at SITC Meeting
Xilio Therapeutics will unveil new clinical and preclinical data at the Society for Immunotherapy of Cancer’s annual meeting on...
Ryoncil® Gets CMS J-Code, Boosting Patient Access
CMS has activated a permanent HCPCS J-code, J3402, for Mesoblast’s Ryoncil (remestemcel‑l‑rknd), effective October 1, 2025. The code creates...